<DOC>
	<DOCNO>NCT01188772</DOCNO>
	<brief_summary>Genotype 1 : Participants genotype 1 hepatitis C ( HCV ) infection randomize receive sofosbuvir ( GS-7977 ; PSI-7977 ) 200 mg 400 mg , match placebo , plus pegylated interferon alfa 2a ( PEG ) ribavirin ( RBV ) 12 week , follow PEG+RBV additional 36 week . Randomization stratify IL28B status ( CC , CT , TT ) HCV RNA level ( &lt; 800,000 IU/ml ≥ 800,000 IU/ml ) baseline . Participants randomize 2:2:1 manner ; achieve extend rapid virologic response ( eRVR ) ( HCV RNA &lt; low limit detection [ 15 IU/mL ] Weeks 4 12 ) receive additional 12 week PEG+RBV . Subjects achieve eRVR receive additional 36 week PEG+RBV . Genotype 2 3 : Participants genotype 2 3 hepatitis C ( HCV ) receive sofosbuvir 400 mg plus PEG+RBV 12 week .</brief_summary>
	<brief_title>Sofosbuvir Combination With Pegylated Interferon Ribavirin Treatment-Naive Hepatitis C-infected Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Males female age 18 70 year , inclusive , screen Documented chronic genotype 1 , 2 , 3 HCV infection No previous treatment HCV antiviral mediation Body mass index ( BMI ) great 18 kg/m2 , exceed 36 kg/m2 . Liver biopsy obtain within 3 year prior Day 1 visit , fibrosis classification noncirrhotic judge local pathologist Willing refrain begin new exercise regimens first 3 month study Fasting blood glucose ≤ 300 mg/dl and/or glycosylated hemoglobin ( HbA1c ) ≤ 8 History hypertension manage effectively stable regimen two few antihypertensive least three ( 3 ) month prior screen Females breastfeed Males female reproductive potential unwilling use `` effective '' , protocolspecified method ( ) contraception study Positive test Screening HBsAg , antiHBc IgM Ab , antiHIV Ab . History clinically significant chronic liver disease Treatment herbal/natural remedy antiviral activity within 30 day prior baseline . Significant history immunologically mediate disease , cardiac pulmonary disease , seizure disorder anticonvulsant use History ascites , variceal hemorrhage , hepatic encephalopathy , condition consistent decompensated liver disease Use medication associate QT prolongation within 30 day prior dose Screening electrocardiogram ( ECG ) QTc value great 450 m and/or clinically significant ECG finding Personal family history Torsade de pointes . Positive result drug abuse test screening Abnormal hematological biochemical parameter , include alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≥ 5 time upper limit normal range ( ULN ) History major organ transplantation exist functional graft History uncontrolled thyroid disease abnormal thyroidstimulating hormone ( TSH ) level screen Clinically significant drug allergy nucleoside/nucleotide analogs History current evidence psychiatric illness , immunologic disorder , pulmonary , cardiac disease , seizure disorder , cancer history malignancy opinion investigator make patient unsuitable study History systemic antineoplastic immunomodulatory treatment within 6 month prior dose , expectation treatment study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Hepatitis C Virus</keyword>
	<keyword>HCV</keyword>
	<keyword>hepatitis</keyword>
	<keyword>Genotype 1</keyword>
	<keyword>Genotype 2</keyword>
	<keyword>Genotype 3</keyword>
</DOC>